Free Trial Information
BioCentury | Jan 7, 2013
Company News

Heart Metabolics board of directors update

...Heart Metabolics Ltd. , London, U.K. Business: Cardiovascular Appointed: Michael Bettess, investment manager at Trans Tasman Commercialization Fund; Andrew...
Read More
BioCentury | Jan 7, 2013
Financial News

Heart Metabolics completes venture financing

...London, U.K. Business: Cardiovascular Date completed: 1/3/13 Type: Venture financing Raised: $4 million Investors: Trans Tasman Commercialization Fund...
Read More
BioCentury | Jan 3, 2013
Financial News

Heart Metabolics closes series A tranche

...raised $4 million in the first tranche of a planned $6 million series A round. Trans Tasman Commercialization Fund...
Read More
BioCentury | Jun 20, 2011
Emerging Company Profile

Pathway: Function follows PI3K isoform

Many PI3K inhibitors in development cause severe side effects that limit dosing, and most mTOR inhibitors have limited effectiveness because they target only one of the two mTOR complexes involved in cancer call growth. Pathway...
Read More
Items per page:
1 - 4 of 4
BioCentury | Jan 7, 2013
Company News

Heart Metabolics board of directors update

...Heart Metabolics Ltd. , London, U.K. Business: Cardiovascular Appointed: Michael Bettess, investment manager at Trans Tasman Commercialization Fund; Andrew...
Read More
BioCentury | Jan 7, 2013
Financial News

Heart Metabolics completes venture financing

...London, U.K. Business: Cardiovascular Date completed: 1/3/13 Type: Venture financing Raised: $4 million Investors: Trans Tasman Commercialization Fund...
Read More
BioCentury | Jan 3, 2013
Financial News

Heart Metabolics closes series A tranche

...raised $4 million in the first tranche of a planned $6 million series A round. Trans Tasman Commercialization Fund...
Read More
BioCentury | Jun 20, 2011
Emerging Company Profile

Pathway: Function follows PI3K isoform

Many PI3K inhibitors in development cause severe side effects that limit dosing, and most mTOR inhibitors have limited effectiveness because they target only one of the two mTOR complexes involved in cancer call growth. Pathway...
Read More
Items per page:
1 - 4 of 4